Have a Patient with Chronic Kidney Disease (CKD) Who May Be Interested in a Genotyping Study?

The study is currently enrolling individuals with CKD not caused by diabetes, a history of proteinuria, and no other identifiable cause of kidney disease to test if they have any apolipoprotein L1 (APOL1) gene variants. Patients may not be aware that this APOL1 gene variation could be the cause of their CKD.

Contact a participating site

About the study

The primary purpose of this investigational genetic testing is to use blood and saliva samples to identify patients with CKD and the APOL1 gene variants, which may qualify them for a future clinical research study.

This clinical research study will require a single study visit where blood and saliva samples will be collected to determine if individuals have changes in the APOL1 gene. This can be done at a study site or in a patient’s home. Changes in the APOL1 gene began more than 10,000 years ago in sub-Saharan Africa; therefore, these APOL1 gene variants are known to occur in individuals of African ancestry. Note: Patients may not identify as having recent African ancestry.

Eligible participants must meet the following criteria:

Are between the ages of 12 and 65 years old (inclusive)

Have diagnosed focal segmental glomerulosclerosis (FSGS) or another form of proteinuric CKD, and no other identifiable cause of kidney disease, including diabetes

Individuals (including but not limited to a first-degree blood relative of an individual with end-stage kidney disease [ESKD]) without a CKD diagnosis may also be considered for participation if they have a historical estimated glomerular filtration ratio (eGFR) of < 75 mL/min
Eligible participants must have proteinuria, which can be confirmed via previously documented result if it was done within 12 months before the date of informed consent or by random spot urine sample using a dipstick test performed during screening

Willing and able to comply with the testing requirements

Contact a participating research site

If you know someone may meet the eligibility criteria and could be interested in learning more about this study, please use the contact form for more information on the study. If you would like to refer a patient to one of our active sites, please fill in your own details in the form below. Circuit Clinical, a service provider working with Vertex Pharmaceuticals on screening for this study, or a member of the study team will contact you.

If you are currently treating a patient who may be interested in this study, please fill out the form below to be contacted by a member of Circuit Clinical, a service provider working with Vertex Pharmaceuticals on screening for this study.